Wednesday, 14 October 2026European Markets

ROCHE BOBOIS And CATANA GROUP Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - roche bobois (rbo.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
roche bobois (rbo.pa) €44.40 5.23% 19.58%
catana group (catg.pa) €4.70 3.34% 29.88%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. roche bobois (rbo.pa)

5.23% forward dividend yield and 19.58% return on equity

roche bobois s.a. engages in the furniture design and distribution business worldwide. it provides living room products, such as sofas and sofa beds, coffee tables, armchairs, wall compositions, cocktail tables, tv units, bookcases, cabinets, side tables, consoles, and occasional furniture; dining room products, including chairs, stools, benches, sideboards, dining tables, columns, dressers, and dining room storage products; desks; bedroom products comprising beds, wardrobes, bedside tables, screens, complements, and other bedroom furniture products; outdoor furniture products; and lights, cushions, rugs, mirrors, decorative objects, and home furnishings, as well as other furniture products. the company offers its products under the roche bobois and cuir center brands. as of march 31, 2022, it operated 128 owned and 210 franchised stores in 56 countries worldwide, as well as an online store. the company was formerly known as furn-invest s.a.s. roche bobois s.a. was founded in 1960 and is headquartered in paris, france.

earnings per share

as for profitability, roche bobois has a trailing twelve months eps of €2.97.

pe ratio

roche bobois has a trailing twelve months price to earnings ratio of 14.95. meaning, the purchaser of the share is investing €14.95 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.58%.

volume

today's last reported volume for roche bobois is 4861 which is 228.22% above its average volume of 1481.

more news about roche bobois.

2. catana group (catg.pa)

3.34% forward dividend yield and 29.88% return on equity

sa catana group manufactures and catamarans and related services in france and internationally. the company markets its products under the catana, bali, and port pin roland brand names. sa catana group was incorporated in 1993 and is headquartered in canet-en-roussillon, france.

earnings per share

as for profitability, catana group has a trailing twelve months eps of €0.63.

pe ratio

catana group has a trailing twelve months price to earnings ratio of 7.46. meaning, the purchaser of the share is investing €7.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.88%.

volume

today's last reported volume for catana group is 31005 which is 51.77% below its average volume of 64291.

yearly top and bottom value

catana group's stock is valued at €4.70 at 07:30 est, way below its 52-week high of €6.66 and way above its 52-week low of €4.09.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, catana group's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth grew by 11.4%, now sitting on 218.17m for the twelve trailing months.

more news about catana group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com